T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?-Reference-Cited by-同舟云学术

T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?

Published:2022-06-30 Issue:26 Volume:139 Page:3681-3687
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Moreau Philippe¹²,Touzeau Cyrille¹²

Affiliation:

1. 1Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France; and

2. 2Nantes Université, INSERM, CRCI2NA, Nantes, France

Abstract

Abstract Bispecific antibodies are monoclonal antibodies targeting both a surface molecule on the malignant plasma cells and CD3 on T cells, leading to tumor cell death by activated T cells. Bispecific antibodies targeting B-cell maturation antigen, GPRC5D or FcRH5, demonstrated promising efficacy with favorable safety profile in patients with triple-class refractory multiple myeloma. This novel immunotherapeutic modality will likely change the treatment paradigm in the coming years.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/139/26/3681/1904521/bloodbld2021014611c.pdf

Reference65 articles.

1. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma;Mateos;Leukemia.,2022

2. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update;Lakshman;Am J Hematol.,2022

3. Novel immunotherapies in multiple myeloma: chances and challenges;Rasche;Haematologica.,2021

4. Idecabtagene icleucel in relapsed and refractory multiple myeloma;Munshi;N Engl J Med.,2021

5. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results;Anderson;J Clin Oncol.,2021

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma;Seminars in Oncology Nursing;2024-10

2. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications;Blood Advances;2024-06-11

3. Current status of bispecific antibodies and CAR-T therapies in multiple myeloma;International Immunopharmacology;2024-06

4. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting;Clinical Lymphoma Myeloma and Leukemia;2024-06

5. Unlocking hope: talquetamab in multiple myeloma treatment: a bispecific breakthrough targeting CD3 and GPRC5D;International Journal of Scientific Reports;2024-05-23